Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.22.1
Commitments and Contingencies (Details Narrative)
3 Months Ended
Nov. 03, 2020
Dec. 13, 2019
USD ($)
$ / shares
shares
Dec. 13, 2019
EUR (€)
shares
Mar. 31, 2022
USD ($)
Mar. 31, 2022
EUR (€)
Mar. 31, 2022
EUR (€)
Dec. 31, 2021
USD ($)
Initial Rent, In Month       $ 7,642      
Right Of Use Assets In Exchange For Right Of Use Liabilities       461,341      
Payable By Company For Services Rendered       9,588      
Stock Option Expenses       803,207      
Payments For Future Research And Collobration       767,678      
Aggerate Amount Payable, Description the Company to pay in aggregate of up to $2.9 million over a period of 22 months            
Long Term Debt Payable       3,365,191      
Grant Repyable       289,006      
Operating Lease Right-of-use Assets       830,257     $ 383,551
Operating Lease Liabilities       843,443      
Short Term Lease Costs       20,854      
Finance Lease Obligations [Member]              
Lease Payable       604,242      
Operating Lease Right of Use Obligations [Member]              
Operating Lease Liabilities       $ 881,024      
Weighted Average Discount Rate       2.45%   2.45%  
Weighted Average Remaining Lease Term       35 years 35 years    
Payment Of Lease Liabilities       $ 55,975      
Operating Lease Expense       72,865      
Stock Incentive Plan [Member]              
Stock Option Expenses       941,848      
Restricted Stock       500,000      
Total Of Stock Option       1,000,000      
Managing Director's Agreement [Member]              
Amount Payable       217      
Royalty Payment       $ 134,217      
Royality       6.00% 6.00%    
Payable In Equal Monthly Installments | €           € 288,000  
Stock Based Compensation Expenses       $ 753,000      
August 2021 [Member]              
Compensation Expenses       805,840      
Accrued Compensation       601,000      
In 2018 [Member] | Walloon Region Government [Member] | Colorectal Cancer Research Agreement [Member]              
Amount Repayable       $ 119,102      
Terms Of Agreement Description       it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received it is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received    
Repayment Of Grants | €           181,500  
Royality On Revenue       3.53% 3.53%    
Grant Receivable | €           605,000  
Grant Repaid By Installments       over 12 years over 12 years    
In 2018 [Member] | BNP Paribas leasing solutions [Member] | Finance Lease Obligations [Member]              
Amount Payable       $ 0      
Purchase Price For The Property | €           € 25,000  
Maturity Date       January 2022 January 2022    
Implicit Interest       1.35%   1.35%  
Leased Equipment Amortized Term       5 years 5 years    
In 2018 [Member] | Clinical Study Research Agreement [Member] | University of Taiwan [Member]              
Collaborative Obligations Amount Due       $ 510,000      
Lease Agreement Expire Period       three-year three-year    
Collaborative Obligations Amount       $ 2,550,000      
In 2010 [Member] | Walloon Region Government [Member]              
Amount Repayable       $ 61,026      
Terms Of Agreement Description       it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received    
Repayment Of Grants | €           € 314,406  
Royality On Revenue       6.00% 6.00%    
Grant Receivable | €           1,050,000.00  
In 2020 [Member] | Walloon Region Government [Member]              
Amount Repayable       $ 57,348      
Terms Of Agreement Description       it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received it is due to pay a 2.89% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €148,500 and the 2.89% royalty on revenue, is equal to the amount of funding received    
Repayment Of Grants | €           148,500  
Royality On Revenue       2.89% 2.89%    
Grant Receivable | €           495,000  
Grant Repaid By Installments       over 10 years over 10 years    
In 2020 [Member] | Walloon Region Government [Member] | Colorectal Cancer Research Agreement [Member]              
Amount Repayable       $ 51,530      
Terms Of Agreement Description       it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received it is due to pay a 4.34% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €278,830 and the 4.34% royalty on revenue, is equal to the amount of funding received    
Repayment Of Grants | €           278,830  
Royality On Revenue       4.34% 4.34%    
Grant Receivable | €           929,433  
Grant Repaid By Installments       over 15 years over 15 years    
In 2016 [Member] | ING [Member] | Long-term Debt [Member]              
Purchase Price For The Property | €           € 1,120,000  
Maturity Date       May 2031 May 2031    
Fixed Interest Rate On Lease       2.62%   2.62%  
Lease Payable       $ 533,346      
In 2016 [Member] | Loan Agreement [Member] | ING [Member] | Long-term Debt [Member]              
Maturity Date       December 2031 December 2031    
Fixed Interest Rate       2.62%   2.62%  
Repayment Of Long-term Loan Amount | €         € 270,000    
Principal Balance Payable       $ 209,267      
Loan Agreement Term       15 years 15 years    
In 2016 [Member] | Loan Agreement [Member] | Namur Invest [Member] | Long-term Debt [Member]              
Maturity Date       December 2023 December 2023    
Fixed Interest Rate       4.85%   4.85%  
Repayment Of Long-term Loan Amount | €         € 440,000    
Loan Agreement Term       7 years 7 years    
Total Long-term Debt       $ 146,891      
In 2016 [Member] | Research Co-operation Agreement [Member] | DKFZ [Member]              
Collaborative Obligations Amount Due       $ 221,913      
Lease Agreement Expire Period       five-year five-year    
Collaborative Obligations Amount | €           € 400,000  
February 5, 2022 [Member] | Loan Agreement [Member] | First Insurance Funding [Member] | Long-term Debt [Member]              
Maturity Date       November 2022 November 2022    
Fixed Interest Rate       3.57%   3.57%  
Repayment Of Long-term Loan Amount | €         € 620,549    
Loan Agreement Term       9 years 9 years    
Total Long-term Debt       $ 551,599      
Agreement Under Amount | €         € 620,549    
November 23, 2021 [Member] | Loan Agreement [Member] | SOFINEX [Member] | Long-term Debt [Member]              
Maturity Date       June 2025 June 2025    
Fixed Interest Rate       5.00%   5.00%  
Repayment Of Long-term Loan Amount | €         € 450,000    
Loan Agreement Term       3 years 5 months 30 days 3 years 5 months 30 days    
Total Long-term Debt       $ 499,304      
Agreement Under Amount | €         € 450,000    
In 2017 [Member] | Loan Agreement [Member] | SOFINEX [Member] | Long-term Debt [Member]              
Maturity Date       September 2024 September 2024    
Fixed Interest Rate       4.50%   4.50%  
Repayment Of Long-term Loan Amount | €         € 1,000,000    
Loan Agreement Term       7 years 7 years    
Total Long-term Debt       $ 665,738      
In 2018 [Member] | Loan Agreement [Member] | Namur Innovation and Growth [Member] | Long-term Debt [Member]              
Maturity Date       June 2022 June 2022    
Fixed Interest Rate       4.00%   4.00%  
Repayment Of Long-term Loan Amount | €         € 500,000    
Loan Agreement Term       4 years 4 years    
Total Long-term Debt       $ 42,250      
In 2019 [Member] | Loan Agreement [Member] | Namur Invest [Member] | Long-term Debt [Member]              
Maturity Date       September 2024 September 2024    
Fixed Interest Rate       4.80%   4.80%  
Repayment Of Long-term Loan Amount | €         € 500,000    
Loan Agreement Term       4 years 4 years    
Total Long-term Debt       $ 405,646      
October 13, 2020 [Member] | Loan Agreement [Member] | Namur [Member] | Long-term Debt [Member]              
Maturity Date       March 2031 March 2031    
Fixed Interest Rate       4.00%   4.00%  
Repayment Of Long-term Loan Amount | €         € 830,000    
Loan Agreement Term       10 years 10 years    
Total Long-term Debt       $ 844,496      
On September 16, 2020 [Member] | Bioinformatic Analytics Of Cell Free DNA [Member]              
Repayment Of Long-term Loan Amount | €         € 54,879    
Total Long-term Debt       16,771      
Additional Cost Of Company | €         € 155,115    
In 2019 [Member] | Collaborative Arrangement, Co-promotion [Member]              
Collaborative Obligations Amount Due       $ 18,994      
Lease Agreement Expire Period       five-year five-year    
Collaborative Obligations Amount       $ 400,000      
Research Collaboration Agreement Description       Company entered into a funded sponsored research agreement with the Texas A&M University (“TAMU”) in consideration for the license granted to the Company for a five-year period for a cost to the Company of up to $400,000 payable over such period Company entered into a funded sponsored research agreement with the Texas A&M University (“TAMU”) in consideration for the license granted to the Company for a five-year period for a cost to the Company of up to $400,000 payable over such period    
October 25, 2019 [Member] | TAMU [Member]              
Non-controlling Interest       7.50% 7.50%    
Equity Interest       12.50% 12.50%    
Additional Interest       5.00% 5.00%    
January 10, 2020 [Member]              
Agrrement Liability   $ 6,535          
Common Stock, Restricted Shares Issued In Exchange Of Purchased Outstanding Shares, Value   $ 333,969          
Restricted Shares Issued | shares   73,263 73,263        
Common Stock, Restricted Shares Issued In Exchange Of Purchased Outstanding Shares, Shares | shares   73,263 73,263        
Weighted Trading Price Per Share | $ / shares   $ 4.56          
Repayment Of Debt | €     € 350,000        
Common Stock Adjusted Amount   $ 357,000          
Holdback Period       9 years 9 years    
Holdback Liabilities       $ 55,404      
Net Liabilities   $ 43,152